vs
Esperion Therapeutics, Inc.（ESPR）与微宏控股（MVST）财务数据对比。点击上方公司名可切换其他公司
Esperion Therapeutics, Inc.的季度营收约是微宏控股的1.7倍（$168.4M vs $96.4M），Esperion Therapeutics, Inc.同比增速更快（143.7% vs -15.0%），过去两年Esperion Therapeutics, Inc.的营收复合增速更高（10.6% vs 8.9%）
Esperion Therapeutics, Inc.是一家上市美国药企，专注开发用于降低低密度脂蛋白胆固醇的口服小分子药物苯哌多酸，公司总部位于密歇根州安娜堡，目前核心研发管线围绕这款降脂创新药物推进，深耕血脂异常治疗领域的创新药物开发。
微宏控股是一家电池科技企业，总部位于美国得克萨斯州斯塔福德，在纳斯达克上市。公司主要面向商用电动汽车与并网储能系统，设计、研发并生产电池组件及电池系统，目前在美国、中国、德国均设有生产基地。
ESPR vs MVST — 直观对比
营收规模更大
ESPR
是对方的1.7倍
$96.4M
营收增速更快
ESPR
高出158.7%
-15.0%
两年增速更快
ESPR
近两年复合增速
8.9%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $168.4M | $96.4M |
| 净利润 | — | $16.5M |
| 毛利率 | — | 1.0% |
| 营业利润率 | 50.6% | -42.7% |
| 净利率 | — | 17.2% |
| 营收同比 | 143.7% | -15.0% |
| 净利润同比 | — | 120.1% |
| 每股收益（稀释后） | $0.32 | $0.19 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ESPRMVST
| Q4 25 | $168.4M | $96.4M | ||
| Q3 25 | $87.3M | $123.3M | ||
| Q2 25 | $82.4M | $91.3M | ||
| Q1 25 | $65.0M | $116.5M | ||
| Q4 24 | $69.1M | $113.4M | ||
| Q3 24 | $51.6M | $101.4M | ||
| Q2 24 | $73.8M | $83.7M | ||
| Q1 24 | $137.7M | $81.4M |
净利润ESPRMVST
| Q4 25 | — | $16.5M | ||
| Q3 25 | $-31.3M | $-1.5M | ||
| Q2 25 | $-12.7M | $-106.1M | ||
| Q1 25 | $-40.5M | $61.8M | ||
| Q4 24 | — | $-82.3M | ||
| Q3 24 | $-29.5M | $13.2M | ||
| Q2 24 | $-61.9M | $-101.6M | ||
| Q1 24 | $61.0M | $-24.8M |
毛利率ESPRMVST
| Q4 25 | — | 1.0% | ||
| Q3 25 | — | 37.6% | ||
| Q2 25 | — | 34.7% | ||
| Q1 25 | — | 36.9% | ||
| Q4 24 | — | 36.6% | ||
| Q3 24 | — | 33.2% | ||
| Q2 24 | — | 32.5% | ||
| Q1 24 | — | 21.2% |
营业利润率ESPRMVST
| Q4 25 | 50.6% | -42.7% | ||
| Q3 25 | -11.4% | 10.5% | ||
| Q2 25 | 8.6% | 17.8% | ||
| Q1 25 | -34.0% | 16.3% | ||
| Q4 24 | -6.4% | -1.2% | ||
| Q3 24 | -31.0% | 7.1% | ||
| Q2 24 | 3.5% | -118.0% | ||
| Q1 24 | 52.5% | -28.4% |
净利率ESPRMVST
| Q4 25 | — | 17.2% | ||
| Q3 25 | -35.9% | -1.2% | ||
| Q2 25 | -15.4% | -116.1% | ||
| Q1 25 | -62.2% | 53.0% | ||
| Q4 24 | — | -72.6% | ||
| Q3 24 | -57.2% | 13.1% | ||
| Q2 24 | -83.9% | -121.4% | ||
| Q1 24 | 44.3% | -30.5% |
每股收益（稀释后）ESPRMVST
| Q4 25 | $0.32 | $0.19 | ||
| Q3 25 | $-0.16 | $0.00 | ||
| Q2 25 | $-0.06 | $-0.33 | ||
| Q1 25 | $-0.21 | $0.05 | ||
| Q4 24 | $-0.14 | $-0.24 | ||
| Q3 24 | $-0.15 | $0.03 | ||
| Q2 24 | $-0.33 | $-0.32 | ||
| Q1 24 | $0.34 | $-0.08 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $167.9M | $105.0M |
| 总债务越低越好 | — | $13.2M |
| 股东权益账面价值 | $-302.0M | $410.5M |
| 总资产 | $465.9M | $1.0B |
| 负债/权益比越低杠杆越低 | — | 0.03× |
8季度趋势，按日历期对齐
现金及短期投资ESPRMVST
| Q4 25 | $167.9M | $105.0M | ||
| Q3 25 | $92.4M | $90.7M | ||
| Q2 25 | $86.1M | $99.7M | ||
| Q1 25 | $114.6M | $90.9M | ||
| Q4 24 | $144.8M | $73.0M | ||
| Q3 24 | $144.7M | $63.6M | ||
| Q2 24 | $189.3M | $68.2M | ||
| Q1 24 | $226.6M | $39.5M |
总债务ESPRMVST
| Q4 25 | — | $13.2M | ||
| Q3 25 | — | $34.4M | ||
| Q2 25 | — | $34.2M | ||
| Q1 25 | — | $41.3M | ||
| Q4 24 | — | $41.1M | ||
| Q3 24 | — | $53.4M | ||
| Q2 24 | — | $34.2M | ||
| Q1 24 | — | $43.0M |
股东权益ESPRMVST
| Q4 25 | $-302.0M | $410.5M | ||
| Q3 25 | $-451.4M | $358.1M | ||
| Q2 25 | $-433.5M | $356.1M | ||
| Q1 25 | $-426.2M | $454.2M | ||
| Q4 24 | $-388.7M | $387.9M | ||
| Q3 24 | $-370.2M | $486.1M | ||
| Q2 24 | $-344.2M | $455.0M | ||
| Q1 24 | $-294.3M | $546.1M |
总资产ESPRMVST
| Q4 25 | $465.9M | $1.0B | ||
| Q3 25 | $364.0M | $1.0B | ||
| Q2 25 | $347.1M | $1.0B | ||
| Q1 25 | $324.0M | $982.9M | ||
| Q4 24 | $343.8M | $951.9M | ||
| Q3 24 | $314.1M | $997.9M | ||
| Q2 24 | $352.3M | $961.4M | ||
| Q1 24 | $373.1M | $1.0B |
负债/权益比ESPRMVST
| Q4 25 | — | 0.03× | ||
| Q3 25 | — | 0.10× | ||
| Q2 25 | — | 0.10× | ||
| Q1 25 | — | 0.09× | ||
| Q4 24 | — | 0.11× | ||
| Q3 24 | — | 0.11× | ||
| Q2 24 | — | 0.08× | ||
| Q1 24 | — | 0.08× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $45.2M | $16.4M |
| 自由现金流经营现金流 - 资本支出 | — | $15.8M |
| 自由现金流率自由现金流/营收 | — | 16.4% |
| 资本支出强度资本支出/营收 | 0.0% | 0.7% |
| 现金转化率经营现金流/净利润 | — | 0.99× |
| 过去12个月自由现金流最近4个季度 | — | $56.1M |
8季度趋势，按日历期对齐
经营现金流ESPRMVST
| Q4 25 | $45.2M | $16.4M | ||
| Q3 25 | $-4.3M | $15.2M | ||
| Q2 25 | $-31.4M | $37.2M | ||
| Q1 25 | $-22.6M | $7.2M | ||
| Q4 24 | $-35.0M | $6.1M | ||
| Q3 24 | $-35.3M | $-5.4M | ||
| Q2 24 | $-7.2M | $111.0K | ||
| Q1 24 | $53.8M | $2.0M |
自由现金流ESPRMVST
| Q4 25 | — | $15.8M | ||
| Q3 25 | — | $1.2M | ||
| Q2 25 | — | $34.3M | ||
| Q1 25 | — | $4.8M | ||
| Q4 24 | — | $5.7M | ||
| Q3 24 | $-35.5M | $-19.6M | ||
| Q2 24 | $-7.3M | $-2.8M | ||
| Q1 24 | $53.8M | $-8.2M |
自由现金流率ESPRMVST
| Q4 25 | — | 16.4% | ||
| Q3 25 | — | 1.0% | ||
| Q2 25 | — | 37.5% | ||
| Q1 25 | — | 4.1% | ||
| Q4 24 | — | 5.1% | ||
| Q3 24 | -68.7% | -19.3% | ||
| Q2 24 | -9.9% | -3.4% | ||
| Q1 24 | 39.0% | -10.1% |
资本支出强度ESPRMVST
| Q4 25 | 0.0% | 0.7% | ||
| Q3 25 | 0.0% | 11.3% | ||
| Q2 25 | 0.0% | 3.1% | ||
| Q1 25 | 0.0% | 2.0% | ||
| Q4 24 | 0.0% | 0.3% | ||
| Q3 24 | 0.3% | 14.0% | ||
| Q2 24 | 0.1% | 3.5% | ||
| Q1 24 | 0.1% | 12.6% |
现金转化率ESPRMVST
| Q4 25 | — | 0.99× | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | 0.12× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | -0.41× | ||
| Q2 24 | — | — | ||
| Q1 24 | 0.88× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ESPR
| Collaboration Revenue | $124.7M | 74% |
| Products | $43.7M | 26% |
MVST
| Europe | $35.1M | 36% |
| CN | $32.5M | 34% |
| US | $21.5M | 22% |
| Other | $7.2M | 8% |
